BWA | JUL 2026 107 The challenge section is best framed around category adoption rather than company-specific distress. Oral appliance therapy continues to compete for clinical attention alongside CPAP, and in many markets the referral pathway still needs to be built more deliberately. SomnoMed’s response has been to invest in medical education, physician relationships, dentist support and digital workflow improvements, rather than simply pushing product volume. There is a longer history behind the product as well. SomnoMed notes that SomnoDent was based on the original invention of Dr. Richard Palmisano, and that the product family has evolved through continuous improvement and scientifically validated development. That helps the company’s profile because it gives the business a clinical-origin story rather than a purely commercial one. What makes SomnoMed a strong feature is that its col laborators are essential to its success. Sleep physicians, dental sleep medicine practitioners and technology partners like iTero all shape how the product is prescribed, fitted and supported. Combined with the company’s stronger FY25 performance and improved operational execution, that ecosystem suggests SomnoMed is building scale in a way that feels grounded, clinically aligned and increasingly repeatable.
RkJQdWJsaXNoZXIy MTE4MTQ=